Real-world Use of Solriamfetol for Excessive Daytime Sleepiness in Patients Reporting Anxiety or Depression in the Real-World SURWEY Study

American Society of Clinical Psychopharmacology (ASCP) May 27– May 30, 2025 Scottsdale, Arizona

Ulf Kallweit, MD¹, Heike Benes, MD², Lothar Burghaus, MD³, Graham M.L. Eglit, PhD⁴, Samantha Floam, DMD⁴, Gregory Parks, PhD⁵, Hasib Bhojwani, MD⁴, Yaroslav Winter, MD⁶ ¹Center for Biomedical Education and Research, University Witten/Herdecke, Witten, Germany; ²Somni bene GmbH Institut für Medizinische Forschung und Schlafmedizin Schwerin, Germany; ³Department of Neurology, Heilig Geist-Hospital Cologne, Germany; ⁴Axsome Therapeutics, New York, New York, USA; ⁵Former Employee of Axsome Therapeutics, New York, USA ⁶Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany

Key Objective

To assess whether solriamfetol is effective in treating excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in patients with self-reported anxiety and/or depression

Introduction

- Psychiatric comorbidities are prevalent in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA)^{1,2}
- Depression and anxiety are particularly common in these patients, with prevalence rates of \geq 30% each^{3,4}
- Efficacy and safety data for wake-promoting agents in these populations are limited
- Solriamfetol (Sunosi[®]) is a dopamine-norepinephrine reuptake inhibitor with agonistic properties at the trace amine-associated receptor 1 and serotonin 1A receptor^{5,6}; it is approved for use in adults in the United States, Canada and select countries in Europe for the treatment of EDS associated with narcolepsy or OSA^{7,8}
- Clinical trials with solriamfetol have excluded patients with severe psychiatric comorbidities, and the prescribing information advises against its use in this population
- As a result, there are limited data available on the efficacy and safety of solriamfetol in these patients

Methods

- **SU**nosi **R**eal **W**orld **E**xperience Stud**Y** (SURWEY) was a retrospective chart review among physicians in Germany who have prescribed solriamfetol to patients with EDS associated with narcolepsy or OSA
- Eligible patients were ≥ 18 years of age, had a diagnosis of EDS and narcolepsy or OSA, had reached a stable maintenance dose of solriamfetol and completed \geq 6 weeks of treatment; patients who received solriamfetol during a clinical trial or early access program were excluded
- The present analysis focused on data from 154 adult patients with narcolepsy or OSA, stratified by self-reported anxiety and/or depression
- Patients were classified as anxious and/or depressed based on their answer at baseline to a single yes/no question
- Data related to comorbidities, Epworth Sleepiness Scale (ESS) scores, patient-and physician-reported improvement in EDS, and adverse events were summarized descriptively
- All efficacy results were pooled across dosages, and most patients took less than the maximum recommended dose of 150mg/day

References

- 1. Fortuyn H, et al. Gen Hosp Psychiatry. 2010;32(1):49-56.
- . Sharafkhaneh A, et al. Sleep. 2005 28(11):1405-11. 3. Kim JY, et al. JAMA Otolaryngol Head Neck Surg. 2019;145(11):1020-
- Garbarino S, et al. Behav Sleep Med. 2020; 18(1):35-57
- 5. Alnefeesi Y, et al. Neurosci Biobehav Rev. 2021;131:192-210. 6. Gursahani H, et al W. Sleep. 2022;45(suppl 1):A329.
- Sunosi[®] (solriamfetol) [Prescribing Information]. New York, NY. Axsome Therapeutics, Inc 8. Sunosi[™] (solriamfetol) tablets Summary of Product Characteristics. Waterford, Ireland: TMC Pharma (EU) Limited; 2022

Acknowledgments

This study was supported by Axsome Therapeutics, Inc. and Pharmanovia

axsome

Disclosures

- U. Kallweit is on the advisory board at, is consultant to, and has accepted research support from Jazz Pharmaceuticals. Takeda Pharmaceuticals, and Bioprojet H. Benes is on the advisory board of Takeda Pharmaceuticals and Idorsia Pharmaceuticals, and has received honoraria for educational presentations from Idorsia
- L. Burghaus has nothing to disclose.
- G.M.L. Eglit and H Bhojwani are an employees of Axsome Therapeutics, Inc. S. Floam is an employee of Axsome Therapeutics, Inc. and former employees of Jazz Pharmaceuticals.
- G. Parks is a former employee of Axsome Therapeutics, Inc. and Jazz Pharmaceuticals Y Winter has received honoraria for educational presentations and consultations from Axsome Therapeutics, Inc., Arvelle Therapeutics, Angelini Pharma, Bayer AG, Bial, Bioprojet Pharma, Bristol Myers Squibb, Eisai, Ethypharm GmbH, GW Pharmaceuticals, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, LivaNova, Neuraxpharm, Novartis, and UCB Pharma

QR Code


Scan the QR code at the top of this poster or access https://www.axsomecongresshub.com/ASCP2025.shtml to view or download a PDF of this poster or access additional information.

Results

č 20

Table 1. Baseline Demographics and Clinical Characteristics

Indication, n (%) Narcolepsy OSA ESS, mean (SD) Age, mean (SD), yea **Sex**, n (%) Female Male BMI **ADHD**, n (%) Other psychiatric dis Other neurological Other sleep disorde ADHD, attention deficit hyperactivity disorder; BMI, body mass index; ESS, Epworth Sleepiness Scale; OSA, obstructive sleep apnea. Baseline demographics were similar between patients with and without self-reported anxiety and/or depression Figure 2. Reductions in ESS Scores for Patients With and Without Anxiety/Depression Narcolepsy OSA Overall Anx/Dep Anx/Dep No Anx/Dep No Anx/Dep **B**^{*} = 17.9 B = 17.5 B = 16.1 B = 16.0 B = 16.7 -1 Mea ESS, **.9** -3 -3.9 nge -4 Chai -4.9 -5.0 -5.2 -5 -5.5 -6 In patients with narcolepsy or OSA, those with anxiety/depression experienced comparable reductions in ESS to those without *B baseline Figure 4. Proportion of Patients and Physicians Reporting Improvement in EDS* 100 80 8 60 Ē



In patients with narcolepsy or OSA, ≥ 88% reported experiencing improvement in EDS, regardless of anxiety/depression status, consistent with physician reports *Patients or physicians rated EDS "slightly improved" or "strongly improved"

	Anxiety/Depression n = 48	No Anxiety/Depression n = 106	Overall N = 154
	25 (52)	46 (43)	71 (46)
	23 (48)	60 (57)	83 (54)
	17.0 (3.3)	16.6 (3.2)	16.7 (3.2)
ars	43.9 (12.8)	42.8 (15.9)	43.1 (15.0)
	21 (44)	48 (45)	69 (45)
	27 (56)	58 (55)	85 (55)
	29.2 (6.2)	29.9 (6.4)	29.7 (6.3)
	1 (2.1)	1 (0.9)	2 (1.3)
isorder , n (%)	0	4 (3.8)	4 (2.6)
disorder, n(%)	4 (8.3)	2 (1.9)	6 (3.9)
er, n (%)	5 (10)	18 (17)	23 (15)









Figure 1. Incidence of Anxiety/Depression in Patients With Narcolepsy or OSA No Anxiety/Depression







	Narcolepsy		OSA		Overall
Adverse event, n (%)	Anxiety/ depression n = 25	No anxiety/ depression n = 46	Anxiety/ depression n = 23	No anxiety/ depression n = 60	N = 154
Headache	2 (8.3)	4 (8.9)	3 (13.0)	4 (6.8)	13 (8.6)
Decreased appetite	1 (4.2)	3 (6.7)	3 (13.0)	3 (5.1)	10 (6.6)
Insomnia	2 (8.3)	2 (4.4)	2 (8.7)	3 (5.1)	9 (6.0)
Irritability	3 (12.5)	0	2 (8.7)	2 (3.4)	7 (4.6)
Other	3 (12.5)	0	0	3 (5.1)	6 (4.0)
Dizziness	1 (4.2)	1 (2.2)	1 (4.3)	2 (3.4)	5 (3.3)
Feeling jittery	1 (4.2)	0	1 (4.3)	3 (5.1)	5 (3.3)

Rates of anxiety/depression were similar between patients with narcolepsy (35.2%) and OSA (27.7%)

No Anx/Dep

Conclusions

- These real-world data describe treatment outcomes of solriamfetol in patients with narcolepsy or OSA, both with and without selfreported anxiety/depression
- Reductions in EDS were substantial and comparable in patients with and without self-reported anxiety/depression
- Most patients and physicians reported improvements in EDS
- These findings are consistent with clinical trial results and suggest that solriamfetol is effective in managing EDS in patients with psychiatric comorbidities

Overall

90 90

No Anx/Dep

OSA Narcolepsy Overall In patients with narcolepsy or OSA, ≥ 88% experienced clinically meaningful improvement in

Anx/Dep

EDS, achieving a reduction of \geq 2 points in ESS score, regardless of anxiety/depression status

Table 2. Adverse Events (≥3% Overall)